Approximately 70-80% of breast cancer patients are estrogen receptor-positive which expressed ER alpha (ER-α), and 10-20% are referred as triple-negative breast cancer (TNBC) which lacks to express ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) [1, 2, 3]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.